ArticleDiscover oncology2026
A novel hypoxia-related signature for predicting prognosis, immune characteristics, and therapeutic response in hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThis study aimed to develop and validate a hypoxia-related gene signature for prognostic assessment in hepatocellular carcinoma (HCC) and to explore its associated biological characteristics and immune features. In addition, a self-established human tissue cohort was used to verify the expression stability of the identified signature genes.
methodsThe TCGA-LIHC cohort was used as the training set to identify differentially expressed hypoxia-related genes associated with overall survival. Least absolute shrinkage and selection operator (LASSO) regression and Cox regression analyses were subsequently applied to construct a prognostic model. The predictive performance of the model was externally validated using the GSE14520 and GSE116174 cohorts. Functional enrichment and immune microenvironment analyses were performed to characterize the biological differences between risk groups. Furthermore, quantitative real-time PCR (qRT-PCR) was conducted in a human tissue cohort, including normal liver tissues, adjacent non-tumorous tissues, and HCC tissues, to validate the expression patterns of the four signature genes (TMEM45A, PPARGC1A, EFNA3, and STC2).
resultsA four-gene hypoxia-related prognostic signature was established and successfully stratified patients into high- and low-risk groups. Patients in the high-risk group exhibited significantly poorer overall survival in both the training and validation cohorts. Functional enrichment analyses revealed that high-risk tumors were associated with activation of pathways related to cell-cycle progression, MYC targets, epithelial-mesenchymal transition, and metabolic reprogramming. Immune analyses demonstrated increased M0 macrophage infiltration and elevated expression of multiple immune checkpoint genes in the high-risk group. qRT-PCR validation further confirmed the differential expression patterns of the four signature genes in human HCC tissues.
conclusionThis four-gene hypoxia-related signature demonstrated robust prognostic performance across multiple independent cohorts and was associated with distinct metabolic and immune characteristics in HCC. qRT-PCR validation further supported the expression stability of the identified genes in human tissues. These findings provide a useful framework for prognostic stratification and future investigation of hypoxia-related biological mechanisms and therapeutic strategies in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.